The Oncology Institute, Inc.
TOI
$3.78
$0.020.53%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 136.56M | 119.80M | 104.41M | 100.27M | 99.90M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 136.56M | 119.80M | 104.41M | 100.27M | 99.90M |
| Cost of Revenue | 117.64M | 102.30M | 87.16M | 85.63M | 85.54M |
| Gross Profit | 18.92M | 17.50M | 17.25M | 14.64M | 14.37M |
| SG&A Expenses | 25.25M | 26.91M | 25.38M | 24.86M | 26.65M |
| Depreciation & Amortization | 1.72M | 1.81M | 1.78M | 1.71M | 1.57M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 144.62M | 131.01M | 114.32M | 112.20M | 113.75M |
| Operating Income | -8.05M | -11.21M | -9.91M | -11.93M | -13.85M |
| Income Before Tax | -16.50M | -17.14M | -19.59M | -13.18M | -16.11M |
| Income Tax Expenses | -- | -131.00K | -- | -- | -- |
| Earnings from Continuing Operations | -16.50M | -17.01M | -19.59M | -13.18M | -16.11M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.50M | -17.01M | -19.59M | -13.18M | -16.11M |
| EBIT | -8.05M | -11.21M | -9.91M | -11.93M | -13.85M |
| EBITDA | -6.33M | -9.41M | -8.13M | -10.22M | -12.28M |
| EPS Basic | -0.14 | -0.15 | -0.21 | -0.14 | -0.18 |
| Normalized Basic EPS | -0.11 | -0.11 | -0.13 | -0.11 | -0.13 |
| EPS Diluted | -0.14 | -0.15 | -0.21 | -0.15 | -0.18 |
| Normalized Diluted EPS | -0.11 | -0.11 | -0.13 | -0.11 | -0.13 |
| Average Basic Shares Outstanding | 97.47M | 93.20M | 77.10M | 75.66M | 75.52M |
| Average Diluted Shares Outstanding | 97.47M | 93.20M | 77.10M | 75.66M | 75.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |